Last reviewed 2026-05-18 · How we verify

Deferiprone sustained-release

ApoPharma · Phase 1 active Small molecule Quality 55/100

Deferiprone sustained-release is a Iron chelator Small molecule drug developed by ApoPharma. It is currently in Phase 1 development. Also known as: Deferiprone.

Deferiprone chelates excess iron by binding to ferric ions, forming stable complexes that are excreted primarily in urine.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Deferiprone sustained-release
Also known as	Deferiprone
Sponsor	ApoPharma
Drug class	Iron chelator
Modality	Small molecule
Phase	Phase 1

Mechanism of action

Deferiprone is a bidentate iron chelator that binds to free iron in a 3:1 molar ratio. By forming stable, water-soluble complexes with ferric ions, it facilitates iron removal from the body through urinary excretion, reducing iron accumulation in tissues and organs.

Approved indications

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Deferiprone sustained-release CI brief — competitive landscape report
Deferiprone sustained-release updates RSS · CI watch RSS
ApoPharma portfolio CI

Frequently asked questions about Deferiprone sustained-release

What is Deferiprone sustained-release?

Deferiprone sustained-release is a Iron chelator drug developed by ApoPharma.

How does Deferiprone sustained-release work?

Deferiprone chelates excess iron by binding to ferric ions, forming stable complexes that are excreted primarily in urine.

Who makes Deferiprone sustained-release?

Deferiprone sustained-release is developed by ApoPharma (see full ApoPharma pipeline at /company/apopharma).

Is Deferiprone sustained-release also known as anything else?

Deferiprone sustained-release is also known as Deferiprone.

What drug class is Deferiprone sustained-release in?

Deferiprone sustained-release belongs to the Iron chelator class. See all Iron chelator drugs at /class/iron-chelator.

What development phase is Deferiprone sustained-release in?

Deferiprone sustained-release is in Phase 1.

Drug class: All Iron chelator drugs
Manufacturer: ApoPharma — full pipeline
Also known as: Deferiprone

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing